Company news

argenx SE news in 2026

argenx SE's news releases, calls and decks from 2026, newest first.

View company

Argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

October 15, 2026

Argenx argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

October 8, 2026

Argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

September 17, 2026

Argenx argenx to Present at Upcoming Investor Conferences

September 1, 2026

Argenx Completes Acquisition of Forte Biosciences, Inc.

August 27, 2026

Argenx argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026

Argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026

Argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 6, 2026

Argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

August 3, 2026

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

July 27, 2026

Argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

July 23, 2026

Argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

July 16, 2026

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

June 3, 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026

Argenx to Present at Upcoming Investor Conferences

May 27, 2026

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

May 8, 2026

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

May 6, 2026

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026

Argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

April 18, 2026

argenx announces Annual General Meeting of Shareholders on May 6, 2026

March 20, 2026

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

March 16, 2026

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

March 6, 2026

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

February 26, 2026

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

February 26, 2026

argenx to Present at TD Cowen 46th Annual Healthcare Conference

February 23, 2026

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

February 19, 2026

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

January 13, 2026

argenx Highlights 2026 Strategic Priorities

January 12, 2026

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

argenx Announces Leadership Transition Marking Next Evolution of Growth

January 5, 2026

Calls in 2026

Decks in 2026